Malaysia within ASEAN Harmonisation: AMDD, Classification and Neighbour Comparison

1. Key takeaways

Malaysia’s classification and conformity assessment framework was designed in alignment with the ASEAN Medical Device Directive (AMDD), and much of what appears to be Malaysian procedure is in fact ASEAN harmonisation expressed in Malaysian instruments. The mandatory problem reporting regime corresponds, in AMDD terms, to adverse event reporting. The two-dimensional risk matrix applied to IVDs, with personal risk on one axis and public health risk on the other, and the CSDT template used for submissions, are both products of that harmonisation. Recognising the ASEAN layer explains why a dossier prepared for one AMDD-aligned market transfers more readily to Malaysia than a dossier prepared for Europe or the United States.

• Classification and conformity assessment in Malaysia are aligned by design with the ASEAN Medical Device Directive.
• Mandatory problem reporting under the Malaysian framework is the AMDD adverse event reporting obligation in local form.
• The IVD risk matrix and the CSDT template are ASEAN harmonised instruments, not Malaysian inventions.
• ASEAN registration is not automatically mutually recognised: a certificate from another member state does not substitute for a Malaysian registration.
• Circular Letter MDA No. 1/2025 creates a verification pathway that substantially reduces repeat assessment for holders of approvals from recognised jurisdictions.
• Singapore and Malaysia share a similar architecture, with four risk levels and a local licence-holder requirement, but the authorities, certificate types, application systems and fee structures are independent and the certificates do not replace each other.

2. Legal basis

The AMDD connection is visible in the instruments themselves. The Third Schedule to the Medical Device Regulations 2012 adopts the CSDT as the submission template, and the CSDT is the ASEAN Common Submission Dossier Template. The classification rules in the First Schedule follow the AMDD risk architecture, including the separate IVD rules in Appendix 2 with their personal and public health dimensions. The vigilance obligation in Section 40 of Act 737, described domestically as mandatory problem reporting, corresponds to the adverse event reporting concept used across the region, a correspondence made explicit in the foreword to MDA/GD/0014 on mandatory problem reporting.

Harmonisation of format is not harmonisation of legal effect. A registration granted in another ASEAN member state does not confer a right to place a device on the Malaysian market, and the Malaysian registration does not travel in the other direction. What the framework does provide is a route by which an approval from a recognised jurisdiction can reduce the depth of repeat assessment. Circular Letter MDA No. 1/2025 establishes that verification pathway, and Table 1 of the Circular identifies the recognised countries and the approval types accepted from each. The list includes the Australian Therapeutic Goods Administration, Health Canada, European notified bodies as recorded in NANDO and EUDAMED, the Japanese Ministry of Health, Labour and Welfare (MHLW), the United States Food and Drug Administration for 510(k) and PMA approvals, and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA).

The comparison with Singapore is instructive because the resemblance is architectural rather than administrative. Both systems use four risk levels from A to D, and both require a locally licensed entity to hold the registration. Beyond that, the authorities differ, since Singapore is regulated by the Health Sciences Authority and Malaysia by the MDA, and the certificate types, application systems and fee structures are separate. A Singapore certificate is evidence of a regulatory history, not a Malaysian authorisation, and the same is true in reverse. Details of the Singapore system should be taken from that authority’s current publications rather than inferred from the Malaysian framework.

3. Expert insights

The strategic implication of the AMDD alignment is that the marginal cost of adding a second or third ASEAN market is lower than the marginal cost of the first, provided the first dossier was built to the harmonised template. A file assembled to the CSDT can be adapted to another member state by adjusting the national modules rather than by rebuilding the technical core. A file assembled to a European or United States structure has to be re-laid into the CSDT before any of that benefit is available, which is why the format decision taken at the beginning of a programme determines the cost of every market that follows.

The verification pathway changes the economics further for manufacturers with existing approvals. Where a device holds a certificate from one of the recognised jurisdictions listed in Table 1 of Circular Letter MDA No. 1/2025, the assessment can rely on that approval rather than repeating the full evaluation, which is where the substantive saving lies. The pathway is not a formality, however: the recognised approval has to be current, it has to cover the device as configured for Malaysia, and the Malaysian file still has to satisfy the CSDT and the national modules.

The sequencing question follows from the same logic. A common approach is to secure the core market that offers the harmonisation benefit first and then extend to neighbouring markets from that base, rather than treating each country as an independent project. For a manufacturer already holding a European MDR certificate, the sequence can be designed around verification pathway combinations, which reduces the amount of duplicate assessment across the region. The administrative discipline that makes this work is an evidence baseline library: one set of test reports and clinical evidence, maintained as the single source, with each country’s CSDT or national template produced by trimming and reformatting from that source rather than by re-authoring. Re-authoring is where inconsistencies between markets are born, and once two markets hold slightly different versions of the same claim, correcting them costs more than the original drafting.

4. Practical recommendations

• Build the technical file to the CSDT from the outset, so that the ASEAN transfer benefit is available for later markets rather than only for Malaysia.
• Keep the AMDD correspondence explicit in the file, mapping mandatory problem reporting to adverse event reporting and the IVD matrix to its two risk dimensions.
• Check eligibility against Table 1 of Circular Letter MDA No. 1/2025 before commissioning a full assessment, and record which recognised approval is relied on.
• Do not treat a certificate from another ASEAN member state or from Singapore as a substitute for a Malaysian registration, and do not plan a launch on that assumption.
• Maintain an evidence baseline library with a single controlled version of each test report and clinical document, and generate country files by trimming rather than rewriting.
• Sequence the regional programme around the harmonised core market first, then extend, so that each additional market inherits a validated file rather than starting a new one.

5. Verification checklist

• □ MDA/GD/0014 on mandatory problem reporting reviewed, including the foreword addressing the AMDD context (pending verification).
• □ Circular Letter MDA No. 1/2025, Table 1, checked for the recognised countries and the approval types accepted from each (pending verification).
• □ Third Schedule to the Medical Device Regulations 2012 confirmed as adopting the CSDT as the ASEAN harmonised template (pending verification).
• □ Appendix 2 to the First Schedule reviewed for the personal and public health risk dimensions applied to IVDs (pending verification).
• □ Any reliance on a foreign approval documented with the certificate number, its scope and its expiry date (pending verification).
• □ Singapore requirements taken from the Health Sciences Authority’s current publications rather than from Malaysian materials (pending verification).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com